Cephalon Receives Approval to Market Modafinil for Shift Work Sleep Disorder in Germany
Cephalon, Inc. announced that the company has received authorization from the Federal Institute for Drugs and Devices (BfArM) to market modafinil tablets in Germany for the treatment of moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients working night shifts, if measures of sleep hygiene have not led to a satisfactory improvement. Marketed under the trade name VIGIL(R), modafinil has been available in Germany since 1998.
"Germany is the third European country to approve modafinil for the treatment of shift work sleep disorder and to recognize the need to treat it. This new indication capitalizes on the strong clinical data surrounding this medication and allows us to improve the quality of life of the people suffering from this debilitating disorder," said Alain Aragues, President, Cephalon Europe.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.